It requires a healthy dose of science to discuss a
very noticeable spike in calls to the N.C. Poison Control Center about adverse reactions to a quasi-legal cousin of the chemical in marijuana. So explanations can be difficult to follow.
Even if youâre not high.
But due to the skyrocketing popularity of such products as edibles, oils and vaping pens that contain delta-8 â ask a teenager if youâre not sure what they are â itâs important to at least try to follow along.
Especially if youâve got a stash of chewable fruit-flavored candies on the nightstand or countertop.
Researchers discover gene that impacts the development of Ewing sarcoma in children
Researchers have discovered a gene, OTUD7A, that impacts the development of Ewing sarcoma, a bone cancer that occurs mainly in children. They have also identified a compound that shows potential to block OTUD7A protein activity. The finding, by scientists at the University of North Carolina and the Lineberger Comprehensive Cancer Center, appeared online June 1, 2021, in
Advanced Science.
About 250 children and young adults are diagnosed with Ewing sarcoma each year in the U.S. About half of those diagnosed will ultimately succumb to the disease, pointing to the need for better therapies.
UNC Lineberger researchers have discovered a gene, OTUD7A, that impacts the development of Ewing sarcoma, a bone cancer that occurs mainly in children. They have also identified a compound that shows potential to block OTUD7A protein activity. Critical relationships between proteins contribute to the development of cancers such as Ewing sarcoma. So, it was a seminal discovery when the UNC researchers found that OTUD7A controls the cancer-causing fusion protein.
Published: May 21, 2021 By Alex Keown
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation.
“Dr. Pollack is an astute and thoughtful higher education leader whose breadth of knowledge and depth of expertise position him well to build on the many strengths of our pharmacy school and cultivate pharmaceutical research scientists and clinicians who are committed to tackling society’s most pressing health care challenges. ”
President Satish K. Tripathi
Gary M. Pollack, professor and dean of the College of Pharmacy and Pharmaceutical Sciences at the University of Toledo, has been appointed dean of the School of Pharmacy and Pharmaceutical Sciences.
The announcement was made today by Provost A. Scott Weber, and Michael E. Cain, vice president for health sciences and dean of the Jacobs School of Medicine and Biomedical Sciences at UB. Pollack will join UB in August.